Status: Recruiting
Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial
The aim of this pilot phase trial is to assess the safety and tolerability, and estimate the efficacy of sirolimus in reducing the incidence of ICH during high-risk periods for rebleeding, compared to placebo. This pilot trial will inform the design of a future definitive clinical trial on sirolimus treatment for CCM.
Participants needed: 75
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Huashan HospitalUpdated: Dec 20, 2024Locations: 2
Eligibility criteria
Age 18-65 years, any gender; [+4]
Cancer history; [+13]